Search Results - "Vallera, Daniel A."

3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments by Meng, Fanben, Meyer, Carolyn M., Joung, Daeha, Vallera, Daniel A., McAlpine, Michael C., Panoskaltsis‐Mortari, Angela

“…The development of 3D in vitro models capable of recapitulating native tumor microenvironments could improve the translatability of potential anticancer drugs…”
Get full text

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells by Arvindam, Upasana Sunil, van Hauten, Paulien M. M., Schirm, Dawn, Schaap, Nicolaas, Hobo, Willemijn, Blazar, Bruce R., Vallera, Daniel A., Dolstra, Harry, Felices, Martin, Miller, Jeffrey S.

“…The low 5-year survival rate for patients with acute myeloid leukemia (AML), primarily caused due to disease relapse, emphasizes the need for better…”
Get full text

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets by Gleason, Michelle K., Ross, Julie A., Warlick, Erica D., Lund, Troy C., Verneris, Michael R., Wiernik, Andres, Spellman, Stephen, Haagenson, Michael D., Lenvik, Alexander J., Litzow, Mark R., Epling-Burnette, Pearlie K., Blazar, Bruce R., Weiner, Louis M., Weisdorf, Daniel J., Vallera, Daniel A., Miller, Jeffrey S.

“…Myelodysplastic syndromes (MDS) are stem cell disorders that can progress to acute myeloid leukemia. Although hematopoietic cell transplantation can be…”
Get full text

CD133, Selectively Targeting the Root of Cancer by Schmohl, Jörg U, Vallera, Daniel A

“…Cancer stem cells (CSC) are capable of promoting tumor initiation and self-renewal, two important hallmarks of carcinoma formation. This population comprises a…”
Get full text

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies by Bachanova, Veronika, Frankel, Arthur E, Cao, Qing, Lewis, Dixie, Grzywacz, Bartosz, Verneris, Michael R, Ustun, Celalettin, Lazaryan, Aleksandr, McClune, Brian, Warlick, Erica D, Kantarjian, Hagop, Weisdorf, Daniel J, Miller, Jeffrey S, Vallera, Daniel A

“…The novel bispecific ligand-directed toxin (BLT) DT2219 consists of a recombinant fusion between the catalytic and translocation enhancing domain of diphtheria…”
Get full text

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors by Oh, Felix, Modiano, Jaime F, Bachanova, Veronika, Vallera, Daniel A

“…Ligand-targeted toxins (LTTs) are bioengineered molecules which are composed of a targeting component linked to a toxin that induces cell death once the LTT…”
Get full text

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer by Kennedy, Philippa R, Vallera, Daniel A, Ettestad, Brianna, Hallstrom, Caroline, Kodal, Behiye, Todhunter, Deborah A, Bendzick, Laura, Hinderlie, Peter, Walker, Joshua T, Pulkrabek, Brittany, Pastan, Ira, Kratzke, Robert A, Fujioka, Naomi, Miller, Jeffrey S, Felices, Martin

“…New treatments are required to enhance current therapies for lung cancer. Mesothelin is a surface protein overexpressed in non-small cell lung cancer (NSCLC)…”
Get full text

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS by Sarhan, Dhifaf, Brandt, Ludwig, Felices, Martin, Guldevall, Karolin, Lenvik, Todd, Hinderlie, Peter, Curtsinger, Julie, Warlick, Erica, Spellman, Stephen R., Blazar, Bruce R., Weisdorf, Daniel J., Cooley, Sarah, Vallera, Daniel A., Önfelt, Björn, Miller, Jeffrey S.

“…Myelodysplastic syndrome (MDS) is a clonal heterogeneous stem cell disorder driven by multiple genetic and epigenetic alterations resulting in ineffective…”
Get full text

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies by Schmohl, Joerg U, Todhunter, Deborah, Taras, Elizabeth, Bachanova, Veronika, Vallera, Daniel A

“…Diphtheria toxin (DT) related targeted toxins are effective in cancer treatment, but efficacy diminishes in time because of their immunogenic potential and/or…”
Get full text

Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model by Dicovitsky, Rose H, Schappa, Jill T, Schulte, Ashley J, Lang, Haeree P, Kuerbitz, Ellen, Roberts, Sarah, DePauw, Taylor A, Lewellen, Mitzi, Winter, Amber L, Stuebner, Kathy, Buettner, Michelle, Reid, Kelly, Bergsrud, Kelly, Pracht, Sara, Chehadeh, Andrea, Feiock, Caitlin, O'Sullivan, M Gerard, Carlson, Tim, Armstrong, Alexandra R, Meritet, Danielle, Henson, Michael S, Weigel, Brenda J, Modiano, Jaime F, Borgatti, Antonella, Vallera, Daniel A

“…EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only…”
Get full text

Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development by Schmohl, Joerg U, Todhunter, Deborah, Oh, Seung, Vallera, Daniel A

“…Targeted toxins require multiple treatments and therefore must be deimmunized. We report a method of protein deimmunization based on the point mutation of…”
Get full text

Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic by Li, Qing, So, Christopher R, Fegan, Adrian, Cody, Vivian, Sarikaya, Mehmet, Vallera, Daniel A, Wagner, Carston R

“…A number of clever recombinant methodologies have been developed that recapitulate the valencies of IgG’s (bivalent) and IgA’s (tetravalent). Although higher…”
Get full text

Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA by Oh, Felix, Felices, Martin, Kodal, Behiye, Miller, Jeffrey S., Vallera, Daniel A.

“…Chemotherapy-refractive multiple myeloma (MM) is serious and life-threatening, and better treatments are urgently needed. BCMA is a prominent marker on the…”
Get full text

Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study by Borgatti, Antonella, Winter, Amber L, Stuebner, Kathleen, Scott, Ruth, Ober, Christopher P, Anderson, Kari L, Feeney, Daniel A, Vallera, Daniel A, Koopmeiners, Joseph S, Modiano, Jaime F, Froelich, Jerry

“…Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly…”
Get full text

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors by Schappa, Jill T., Frantz, Aric M., Gorden, Brandi H., Dickerson, Erin B., Vallera, Daniel A., Modiano, Jaime F.

“…Targeted toxins have the potential to overcome intrinsic or acquired resistance of cancer cells to conventional cytotoxic agents. Here, we hypothesized that…”
Get full text

Immunotoxins Targeting B cell Malignancy-Progress and Problems With Immunogenicity by Vallera, Daniel A, Kreitman, Robert J

“…Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and…”
Get full text

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells by Don Yun, Hyun, Felices, Martin, Vallera, Daniel A., Hinderlie, Peter, Cooley, Sarah, Arock, Michel, Gotlib, Jason, Ustun, Celalettin, Miller, Jeffrey S.

“…•NK cell natural cytotoxicity and antibody-dependent cellular cytotoxicity of patients with systemic mastocytosis are normal.•Trispecific killer engagers…”
Get full text

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma by Waldron, Nate N., Barsky, Sanford H., Dougherty, Phillip R., Vallera, Daniel A.

“…The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of…”
Get full text

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma by Oh, Seunguk, Stish, Brad J, Sachdev, Deepali, Chen, Hua, Dudek, Arkadiusz Z, Vallera, Daniel A

“…Purpose: To develop a targeted biological drug that when systemically injected can penetrate to metastatic breast cancer tumors, one needs a drug of high…”
Get full text

Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy by Davis, Zachary B., Vallera, Daniel A., Miller, Jeffrey S., Felices, Martin

“…•Natural killer cell function is negatively regulated by the tumor microenvironment.•Checkpoint receptor blockade has the potential to restore NK…”
Get full text